B7-33 6 mg

Steroids Dragon Pharma Peptide

$26.40

B7-33 6 mg – Peptide Hubs

B7-33 is a synthetic peptide and selective analog of human relaxin-2, specifically designed to target and activate the RXFP1 receptor with minimized hormonal activity. The 6 mg lyophilized vial by Peptide Hubs offers researchers a highly stable, precise format for studying fibrotic conditions, cardiac and pulmonary remodeling, and wound healing responses.

What Is B7-33?

B7-33 is a single-chain variant of relaxin-2 that retains anti-fibrotic signaling via the RXFP1 receptor without triggering the reproductive or vasodilatory side effects typical of native relaxin. It is considered a promising candidate in the field of organ fibrosis, particularly in liver, heart, and lung tissues. Researchers value B7-33 for its ability to modulate TGF-β1 signaling and reduce tissue scarring.

Mechanism of Action

B7-33 selectively binds to the relaxin family peptide receptor 1 (RXFP1), stimulating downstream signaling pathways that reduce fibrotic activity and collagen deposition. Unlike full relaxin-2, it does not activate secondary receptors tied to systemic vasodilation or reproductive hormones. This selectivity makes B7-33 ideal for studies focused on anti-fibrotic outcomes. For in-depth biological data, see this NIH publication on B7-33.

Research Applications

B7-33 is used in preclinical research involving organ protection, tissue remodeling, and systemic or localized fibrotic disorders. It has been studied in models of myocardial infarction, pulmonary fibrosis, and kidney injury. Some experimental protocols also examine B7-33's synergy with compounds like BPC-157 and GHK-CU for regenerative medicine research.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:

Steroids

Brand: Dragon Pharma

Manufacturer: Dragon Pharma

Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage & Usage Guidelines</h2> <ul> <li><strong>Dose:</strong> 3–6 mg/day depending on application</li> <li><strong>Administration:</strong> Subcutaneous injection</li> <li><strong>Duration:</strong> 7–20 days, based on tissue regeneration goals</li> </ul> <p>In inflammation-related protocols, researchers also co-administer ARA-290 or Semax for broader neuroprotective or anti-inflammatory effects.</p> <h3>Stacking Combinations</h3> <p>To enhance the research outcomes of B7-33 in tissue recovery and wound repair, common combinations include:</p> <ul> <li>BPC-157 – muscle and tendon healing</li> <li>GHK-CU – for skin and collagen regeneration</li> <li>AOD 9604 – metabolic support in post-injury studies</li> </ul> <h3>Side Effects & Legality</h3> <p>B7-33 is not associated with hormonal side effects or estrogenic activity. It is non-toxic to the liver and does not influence androgenic pathways, blood pressure, or aromatization. B7-33 is strictly sold for research purposes and is not FDA-approved for human use. For trial data and safety info, refer to the <a href="https://clinicaltrials.gov/" rel="noopener" target="_blank">ClinicalTrials.gov database</a>.</p> </section> </div>

Reviews:

(0 customer reviews)